Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Prothena (PRTA – Research Report), Y-Mabs Therapeutics (YMAB – Research Report) and Aerovate Therapeutics (AVTE – Research Report).
Prothena (PRTA)
In a report released yesterday, Robert Hazlett from BTIG maintained a Buy rating on Prothena, with a price target of $65.00. The company’s shares closed last Friday at $48.47.
According to TipRanks.com, Hazlett is a 2-star analyst with an average return of
Currently, the analyst consensus on Prothena is a Strong Buy with an average price target of $77.29.
See Insiders’ Hot Stocks on TipRanks >>
Y-Mabs Therapeutics (YMAB)
In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Y-Mabs Therapeutics, with a price target of $6.00. The company’s shares closed last Friday at $5.01, close to its 52-week low of $2.94.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
Y-Mabs Therapeutics has an analyst consensus of Hold, with a price target consensus of $10.25.
Aerovate Therapeutics (AVTE)
BTIG analyst Julian Harrison reiterated a Buy rating on Aerovate Therapeutics yesterday and set a price target of $27.00. The company’s shares closed last Friday at $20.17.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerovate Therapeutics with a $35.50 average price target, representing an 85.3% upside. In a report issued on March 30, Jefferies also maintained a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PRTA:
- Piper Sandler healthcare analysts to hold an analyst/industry conference call
- Prothena says no cash deposits or securities at Silicon Valley Bank
- Prothena sees FY23 cash burn of $213-$229M
- Prothena reports Q4 EPS 12c, consensus (47c)
- TipRanks ‘Perfect 10’ List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks
